biotech
Ceftobiprole Effective Against MRSA and VRSA
Filed in archive Drugs, Vaccines and Therapeutics , Microbiology by ruth on July 4, 2008
Ceftobiprole Effective Against MRSA and VRSA
The broad-spectrum antibiotic Ceftobiprole, discovered by Swiss company Basilea Pharmaceuticals, has been demonstrated to be effective against some of the deadliest strains of multiple-resistant Staphylococcus aureus (MRSA), including those strains which have developed resistance the antibiotic vancomycin (VRSA).

The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy and available online now, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. "It just knocked out the cells 100 percent," says the study's lead investigator, Alexander Tomasz, head of the Laboratory of microbiology at Rockefeller.


In photo: Strains of bacteria that are resistant to the antibiotic vancomycin grow easily in its presence (top), but are completely eliminated (bottom) when exposed to Ceftobiprole.


Source


Permalink: Ceftobiprole Effective Against MRSA and VRSA
Tags: MRSA  Staphylococcus  s+aureus  multiple+resistance  antibiotics  VRSA  Ceftobiprole  against  effective+aga 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/128065
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Ceftobiprole Effective Against MRSA and VRSA:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 1 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!